Off-label psychopharmacologic prescribing for children: History supports close clinical monitoring

Pharmaceutical Health Services Research, School of Pharmacy, University of Maryland, Baltimore, Maryland, USA.
Child and Adolescent Psychiatry and Mental Health 10/2008; 2(1):24. DOI: 10.1186/1753-2000-2-24
Source: PubMed


The review presents pediatric adverse drug events from a historical perspective and focuses on selected safety issues associated with off-label use of medications for the psychiatric treatment of youth. Clinical monitoring procedures for major psychotropic drug classes are reviewed. Prior studies suggest that systematic treatment monitoring is warranted so as to both minimize risk of unexpected adverse events and exposures to ineffective treatments. Clinical trials to establish the efficacy and safety of drugs currently being used off-label in the pediatric population are needed. In the meantime, clinicians should consider the existing evidence-base for these drugs and institute close clinical monitoring.

Download full-text


Available from: PubMed Central · License: CC BY
  • Source
    • "Study cohort was limited to patients aged 6 to 16 years at index date as most of the stimulants are indicated for this age group (U.S. Department of Health and Human Services; Zito et al., 2008). Patients were excluded from the cohort if they used AAP during the 6-month baseline period or were diagnosed with any congenital anomalies or hereditary heart diseases anytime during the entire study period. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: This study examined cardiovascular safety of concomitant use of long-acting stimulants (LAS) and atypical antipsychotics (AAP) in children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD). Method: The study used 2004-2007 IMS LifeLink™ claims data involving 6- to 16-year-old children with ADHD and at least one LAS prescription from July 2004 to December 2006. Time-dependent Cox regression analysis was performed to evaluate the risk of cardiovascular disease (CVD) events due to concomitant use of LAS and AAP. Results: The analytical cohort consisted of 37,903 children: 538 (1.9%) used LAS and AAP concurrently and the rest used LAS monotherapy. Time-dependent Cox regression analysis revealed no difference in CVD risk among concomitant users of LAS and AAP (hazard ratio = 1.19; 95% confidence interval = [0.60, 2.53]) when compared with users of LAS monotherapy. Conclusion: Concomitant use of LAS and AAP was not associated with risk of CVD events in ADHD patients when compared with LAS monotherapy.
    Full-text · Article · Oct 2015 · Journal of Attention Disorders
  • Source
    • "Aufgrund unreifer Zielstrukturen und besonderer Stoffwechselbedingungen (Pharmakokinetik) besteht einerseits eine höhere Vulnerabilität für UAW durch erhöhte Plasmaspiegel , andererseits die Gefahr einer ineffektiven Behandlung durch unzureichende Wirkspiegel. Da in rund 10 % der pädiatrischen klinischen Studien mäßige bis schwere UAW vorkommen, die sehr ernsthafte Folgen wie Krankenhausaufenthalte oder Behinderung nach sich ziehen können (Sammons et al., 2008), ist eine systematische Nutzen-Risiko-Abwägung der Pharmakotherapie in dieser Altersgruppe besonders notwendig (Egberts, Mehler- Wex & Gerlach, 2011; Zito et al., 2008). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Rational pharmacotherapy is a challenging task in child and adolescent psychiatry. Increasing prescription numbers contrast with the uncertainties of safety and efficacy issues. The lack of clinical (authorization) trials often implies a non- age-specific use of drugs. However, young patients show particular metabolic conditions and a higher vulnerability for adverse drug reactions. Thus it seems mandatory to create age-specific pharmacological data about efficacy and safety of psychotropic drug use in minors. Legislation authorities became aware of this situation and introduced European and national scientific pharmacovigilance regulations and programmes accordingly in order to continuously evaluate the benefit-risk-ratio, detect, collect, minimize, and prevent adverse effects of drugs by appropriate measures, e.g., therapeutic drug monitoring. In this paper the principles and needs of pharmacovigilance in child and adolescent psychiatry are discussed. Furthermore a large multicenter clinical trial («TDM-VIGIL»), funded by the German Federal Institute for Drugs and Medical Devices, is presented, which appeals to collect epidemiological prescription and safety data of psychotropic drugs in children and adolescents using an internet-based data infrastructure (patient registry).
    Full-text · Article · Jan 2015 · Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie
  • Source
    • "), ist eine systematische Nutzen-Risiko-Abwägung der Pharmakotherapie in dieser Altersgruppe besonders notwendig (Egberts, Mehler- Wex & Gerlach, 2011; Zito et al., 2008). Ein zusätzlich erschwerender Faktor für eine rationale Therapie mit Psychopharmaka bei Kindern und Jugendlichen ist, dass ein Teil der kinder-und jugendpsychiatrischen Patienten (z. "

    Full-text · Article · Aug 2014 · Pharmacopsychiatry
Show more